Introduction
Vertigo is a common symptom encountered in the emergency department (ED). It adversely affects many quality-of-life aspects. Benign paroxysmal positional vertigo (BPPV) and, to a lesser extent, Ménière disease (MD) account for a considerable number of patients seeking medical help in EDs.
BPPV is characterized by brief, recurrent attacks of vertigo triggered by changes in head position. The attacks may be followed by residual dizziness in some patients. With the use of canalith repositioning maneuvers, management of BPPV is usually easy for most patients. 1 MD is a disease of the peripheral vestibular system characterized by repetitive attacks of vertigo, tinnitus, and low-frequency hearing loss. Although many factors such as genetics, allergy, autoimmunity, and stress are presumed to have a role in the etiology of MD, the exact pathophysiologic changes have not been elucidated. 2, 3 The hypothalamic pituitary adrenal axis, autonomic nervous system, and immune system are interrelated components of the stress response. The role of stress has been documented in inner ear diseases in many studies. 4, 5 Studies showed the vestibular system and the autonomic system to be closely related since vestibular activity influences the cardiovascular system. Central anatomic connections between vestibular nuclei and the autonomic pathways have been identified. 6 In addition, stress hormones have been reported to modify inner ear functions such as threshold shifts. 7 Horner reported prolactin to have a role in MD by its effect on osmoregulatory mechanisms. 6 Together with growth hormone, prolactin is now considered a major stress-induced hormone. 8 Yildiz et al showed a marked asymmetric sympathetic hypofunction in the area of the postauricular region of the involved ear in patients with MD. 9 The hypofunction was demonstrated with the use of sympathetic skin responses in the postauricular area. Yamada et al reported autonomic nervous dysfunction to be a predisposing factor in MD using heart rate variability. 10 However, the question of whether it occurs as a triggering factor or a consequence of vertigo in MD was not determined in that study.
MD and BPPV are different entities. Although idiopathic in most cases, BPPV can be observed after MD attacks. BPPV that occurs after inner ear diseases, including MD, has been shown to have a higher recurrence rate and a longer recovery period. AudigyMedical.com/member-stories.
KorKmaz, Bicer, Serin, Seyhan, Sanal an association between residual dizziness in BPPV and sympathoneural autonomic dysfunction. 13 Pezzoli et al also hypothesized autonomic dysfunction to have a role in orthostatic dizziness after recovery of BPPV attacks. 14 However, they failed to show any significant relation between BPPV and orthostatic dizziness through the use of the head-up tilt test.
Salivary α-amylase is a peptide with sympathetic activity and so affects the autonomic nervous system. Many studies in the literature use salivary α-amylase as a marker of sympathetic activity. [15] [16] [17] Instead of employing venous puncture, obtaining saliva is a noninvasive and cost-effective method to measure α-amylase.
Our objective in this study was to demonstrate possible autonomic dysfunction with the use of salivary α-amylase measurements during and after the vertigo attacks of MD and BPPV. Patients. Patients with a diagnosis of MD attacks or BPPV were recruited from EDs. Patients 18 to 65 years old who agreed to participate were included in the study. A bedside confirmation of the attacks was performed by the otolaryngologists according to the criteria recommended by the Committee on Hearing and Equilibrium of the American Academy of Otolaryngology-Head and Neck Surgery. 18 The control group consisted of patients presenting to the ED with acute, minor soft-tissue injuries (i.e., bruises) who were willing to participate in the study. The routine workup was performed for these patients together with the saliva sampling.
Patients and methods
Exclusion criteria included use of medications with an effect on the central nervous system, drinking alcohol or acidic beverages, or doing physical exercise within the preceding 1 hour.
Saliva collection and amylase analysis. Saliva was collected three times from all patients with MD and BPPV and two times from participants in the control group. The first sample was obtained shortly after the patients arrived. For patients with MD, the first sample was obtained during the attack (before any medication use). The second sample was obtained on the third day, and the third sample was obtained on the fifteenth day.
Saliva collection was performed as follows: the patients were asked to collect their saliva for 5 minutes. After its collection, the sample was frozen at -20°C. All samples were unfrozen at 4 to 8°C on the same day. A supernatant was prepared by centrifuging the samples at 1,500 rpm for 10 minutes. Salivary α-amylase analysis of these supernatants was performed after adequate dilution using Siemens Advia 2400 kits (Erlangen, Germany).
Statistical analysis. SPSS for Windows (version 17.0, IBM; Armonk, New York) was used for statistical analysis. All data are presented as the mean ± standard deviation. Associations between salivary α-amylase measures were evaluated using the Wilcoxon signed rank test. Comparison between group means was carried out using the Kruskal-Wallis test at the significance level of p < 0.05. Multiple comparisons were performed using the post hoc Mann-Whitney U test with Bonferroni correction. Bonferroni correction was conducted manually, and values at the level of p < 0.016 were considered significant for post hoc analysis.
Results
Patients who did not come for the repeated saliva measurements were excluded from the study. Also, if it was determined that patients did not have MD or there was a residual vertiginous symptom at the time of the second or third measurement, they were excluded from the study.
Overall, 15 patients in the MD group, 9 patients in the BPPV, and 10 participants in the control group were included in the study. The MD group consisted of 10 men and 5 women aged 18 to 62 years (mean: 39 years). The BPPV group consisted of 2 men and 7 women aged 21 to 65 years (mean: 38 years), and the control group included 6 men and 4 women aged 24 to 62 years (mean: 46 years).
Patients in the MD group had experienced at least two attacks of vertigo previously. Five of the 15 patients had experienced at least 10 attacks. All patients with BPPV were diagnosed with posterior canal BPPV.
In patients with MD, the mean level of salivary α-amylase on first, second, and third measurements were 2,676 ± 4,110 U/l, 1,106 ± 1,411 U/l, and 1,811 ± 2,338 U/l, respectively. Values were 2,087 ± 1,357 U/l, 236 ± 237 U/l, and 813 ± 1,169 U/l in sequential order in patients with BPPV, and 1,020 ± 2,089 U/l and 2,210 ± 8,736 U/l on the first and second measurements of the control group.
The statistical analysis revealed no significant difference among the three groups with respect to the first salivary α-amylase measurements (p > 0.05). The second salivary α-amylase measurement on the third day of the vertigo attack (defined as early after the attack) was significantly different in the BPPV group compared with controls (p = 0.024).
No significant difference was detected in salivary α-amylase levels between the patients with MD and those with BPPV (p = 0.055); however, a significant difference between the BPPV and control groups was found (p = 0.008). No significant difference was found in salivary α-amylase measurements between the MD and control groups. In the BPPV group, however, a significant difference was observed between the first and second salivary α-amylase measurements (p = 0.038) and between the second and third salivary α-amylase measurements (p = 0.008).
The second measurements in the control group could be considered normal values since those patients had only minor soft-tissue injuries. A comparison of those values to the first measurements taken in the MD and BPPV groups revealed no significant difference between groups.
Discussion
Salivary α-amylase is a member of glucosyl hydrolases and is produced mainly in the parotid glands. Its main role is degradation of carbohydrates. Numerous investigators have proposed salivary α-amylase to be a marker of the adrenergic system. It was shown to be secreted from the salivary glands mainly in response to beta adrenergic and partly to alpha adrenergic stimuli.
Salivary α-amylase has been advocated as a biologic marker of physiologic and psychological stress. The interaction between the autonomic nervous system and stress is well known. Many studies have demonstrated a marked increase in salivary α-amylase in anxiety-related diseases, post-traumatic stress, and mental disorders. 15, [17] [18] [19] Sympathetic innervation and the presence of stress hormone receptors in the inner ear tissue are evident. 20 Steroid hormones are shown to slowly modify the inner ear physiology via changing gene expressions or nongenomic pathways. Possible multiple interactions between the sympathetic and the complex feedback neuroendocrine systems have been proposed. Via interacting with the immune system, these interactions and the cytokines contribute to inner ear pathologies such as tinnitus, hearing loss, and vertigo. 21 In noise trauma, for example, even though glucocorticoids are not the sole actors, a more rapid recovery has been observed in adrenalectomized animals. 22 Vasopressin, also known as antidiuretic hormone, is secreted in the hypothalamus and is associated with corticotrophin-releasing hormone. It stimulates adenylate cyclase activity both in the stria vascularis and semicircular canal epithelium and has been reported to be elevated under psychological stress conditions. [23] [24] [25] Vasopressin levels are increased with endolymphatic hydropic states and are associated with vertigo attacks. 26, 27 Takeda et al demonstrated that the administration of vasopressin, which increases the activity of aquaporin 2, to guinea pigs over 1 week resulted in the development of hydrops. 26 Because evidence supports stress-related inner ear pathologies, we aimed to demonstrate possible autonomic dysfunction in MD and BPPV with salivary α-amylase measurements. The first salivary α-amylase measurements (during the vertigo episode) in all the groups were highest compared with subsequent measurements. This finding may be attributed to sympathetic over-reactivity caused by the stress of the attack itself in addition to the stress provoked by the atmosphere of the ED.
Patients with MD demonstrated the highest levels of salivary α-amylase during their attacks. Our statistical analysis supports our hypothesis of increased sympathetic activity during the vertigo attacks, although the difference was not significant. However, a noteworthy finding was the undulating pattern of the salivary α-amylase measurements; salivary α-amylase levels decreased initially at the second measurement and increased again in the following days. We therefore believe that repeating such types of studies with a bigger sample size may reveal more striking results.
The results of the second amylase measurements provide a clue about the role of the autonomic nervous system in these diseases. The difference between the second measurements of salivary α-amylase was significantly lower in BPPV patients than in the MD and control patients. Therefore, a depression in sympathetic tone or a parasympathetic overactivation might be responsible.
The autonomic nervous system with its sympathetic and parasympathetic subdivisions should be in balance to avoid disease states. Disruption of this balance in either hyperadrenergic or hypervagal mixed states can result in a variety of symptoms such as dizziness, palpitations, anxiety, fatigue, syncope, and gastrointestinal symptoms. 28 Although autonomic dizziness is generally considered to be lightheadedness, vertigo in association with autonomic dysfunction is being reported more frequently. [28] [29] [30] Low et al reported vertigo as a symptom of orthostatic hypotension in 37% of cases. 29 Although the lightheadedness is believed to occur as a result of a transient acute decrease in cerebral blood flow, the mechanism of vertigo is still poorly understood. 28 The underlying mechanisms of BPPV have been better elucidated than those of MD or other hydropic states. Residual dizziness is a commonly encountered condition after BPPV. 14 Kim and Lee reported a 43% rate of dizziness after successful canalith repositioning maneuvers. 13 This by itself points to a connection of some type between BPPV and the autonomic nervous system. The mentioned reports demonstrated autonomic dysfunction by means of the head-up tilt test. Our aim in this study was to determine whether this autonomic dysfunction was also possible during vertigo attacks by using a relatively simple method-measurement of salivary α-amylase levels during the attacks.
In BPPV, salivary α-amylase levels were lowest on the third day and then rose again on the 15th day. This result points to a possible imbalance in the autonomic nervous system in BPPV. This possibility is important during follow-up; the clinician should keep in mind that an autonomic dysfunction is possible and should evaluate patients by repeating the maneuvers.
KorKmaz, Bicer, Serin, Seyhan, Sanal Salivary α-amylase is accepted to reflect sympathetic tone. A possible autonomic imbalance in peripheral vertigo might be due to a change in parasympathetic tone. This possibility needs further studies.
The timing of the second and third measurements of salivary α-amylase in our study can be criticized. As no globally accepted normal range of salivary α-amylase currently exists, we compared its levels in patients with different diseases and in patients presenting to the ED with minor soft-tissue trauma and no history of vertigo. The second measurements in the control group can be considered normal values.
Cochleovestibular physiology is affected by the autonomic nervous system. Many mechanisms in the etiology of MD and BPPV have been proposed. The results of our study related to salivary α-amylase levels suggest an autonomic imbalance early after the canalith repositioning maneuvers in BPPV but do not support autonomic dysfunction in MD.
To the best of our knowledge, this study is the first to measure salivary α-amylase in patients with inner ear diseases. Further studies with a larger sample size are required to identify salivary α-amylase as a possible biomarker of autonomic imbalance in patients with vertigo. Diagnosis of vertigo in the ED can be challenging, and there is a continued need for a reliable method to differentiate causes of vertigo.
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